Protective Effect of Isorhamnetin on Lipopolysaccharide-Induced Acute Lung Injury in Mice. 2016

Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
Department of Thoracic Surgery, Tianjin First Center Hospital, No. 24 FuKang Road, Tianjin, 300192, People's Republic of China.

Isorhamnetin has been reported to have anti-inflammatory, anti-oxidative, and anti-proliferative effects. The aim of this study was to investigate the protective effect of isorhamnetin on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice by inhibiting the expression of cyclooxygenase-2 (COX-2). The effects of isorhamnetin on LPS-induced lung pathological damage, wet/dry ratios and the total protein level in bronchoalveolar lavage fluid (BALF), inflammatory cytokine release, myeloperoxidase (MPO) and superoxide dismutase (SOD) activities, and malondialdehyde (MDA) level were examined. In addition, the COX-2 activation in lung tissues was detected by Western blot. Isorhamnetin pretreatment improved the mice survival rates. Moreover, isorhamnetin pretreatment significantly attenuated edema and the pathological changes in the lung and inhibited protein extravasation in BALF. Isorhamnetin also significantly decreased the levels of inflammatory cytokines in BALF. In addition, isorhamnetin markedly prevented LPS-induced oxidative stress. Furthermore, isorhamnetin pretreatment significantly suppressed LPS-induced activation of COX-2. Isorhamnetin has been demonstrated to protect mice from LPS-induced ALI by inhibiting the expression of COX-2.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008315 Malondialdehyde The dialdehyde of malonic acid. Malonaldehyde,Propanedial,Malonylaldehyde,Malonyldialdehyde,Sodium Malondialdehyde,Malondialdehyde, Sodium
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D011654 Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening. Wet Lung,Edema, Pulmonary,Edemas, Pulmonary,Pulmonary Edemas,Lung, Wet,Lungs, Wet,Wet Lungs
D011794 Quercetin A flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin. 3,3',4',5,7-Pentahydroxyflavone,Dikvertin
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations

Related Publications

Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
May 2019, International immunopharmacology,
Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
January 2014, European journal of pharmacology,
Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
January 2011, Respiration; international review of thoracic diseases,
Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
April 2011, Pulmonary pharmacology & therapeutics,
Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
December 2014, International immunopharmacology,
Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
December 2012, Inflammation,
Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
November 2013, The Journal of surgical research,
Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
August 2014, Inflammation,
Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
December 2009, International immunopharmacology,
Bo Yang, and Xiao-Ping Li, and Yun-Feng Ni, and Hong-Yin Du, and Rong Wang, and Ming-Jiang Li, and Wen-Chen Wang, and Ming-Ming Li, and Xu-Hui Wang, and Lei Li, and Wei-Dong Zhang, and Tao Jiang
August 2017, Cellular and molecular biology (Noisy-le-Grand, France),
Copied contents to your clipboard!